Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) is closely associated with minimally invasive Microwave Ablation (MWA) technology for the treatment of benign and malignant tumors. The BDMD news page on Stock Titan aggregates company-specific updates so readers can follow how Baird Medical’s medical devices and minimally invasive treatment technologies are being used and introduced in clinical settings around the world.
News about Baird Medical often highlights clinical milestones, such as first procedures in new countries, successful thyroid and liver tumor ablations, and applications of its MWA systems in bone tumor cases. Releases also describe physician training initiatives, including advanced MWA training sessions and participation in international workshops focused on thyroid microwave ablation and thermal ablation techniques.
Another recurring theme in BDMD news is global expansion and regulatory progress. The company reports regulatory approvals and product registrations in markets such as Pakistan and Vietnam, as well as entry into countries including Egypt and Bangladesh. Announcements have also covered the establishment of a U.S. manufacturing base through a partnership with MPS Medical to support worldwide supply of its proprietary technologies.
Investors and healthcare professionals can use this news feed to monitor developments related to Baird Medical’s microwave ablation devices, its presence in leading hospitals and clinics, and its broader commercialization and training activities. For ongoing insight into BDMD stock from a news perspective, this page provides a focused view of the company’s clinical, regulatory, and operational updates.
Baird Medical (NASDAQ: BDMD) participated in a two-day Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz, National University of Malaysia on Oct 1–2, 2025.
The immersive program combined lectures, complex case discussions and hands-on training with mannequins and live patient cases led by Proctor Dr. Shuhang Xu and HCTM faculty Dr. Adi Syazni and Prof. Shahrun Niza. Baird Medical supplied expertise and support to advance physician skills in minimally invasive Microwave Ablation (MWA) and to promote wider clinical adoption of MWA therapy in the region.
Baird Medical (NASDAQ: BDMD) participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism held in Beijing on October 17-18, 2025 at the China-Japan Friendship Hospital.
Chaired by Prof. Ming'an Yu, the workshop featured live procedures, clinical exchanges, and advanced technique discussions. Baird Medical said its presence highlights a commitment to international collaboration, sharing best practices for Microwave Ablation (MWA), and advancing minimally invasive thyroid care.
Baird Medical (NASDAQ: BDMD) announced its microwave ablation (MWA) system was successfully used in two minimally invasive procedures at UCSF Health on Oct 16, 2025.
Interventional radiologist Dr. Alexander Lam treated two patients with benign thyroid nodules measuring 5.0 cm and 6.5 cm, avoiding surgery. Active treatment time averaged less than 25 minutes per case; both patients remained comfortable under local anesthesia and reported minimal pain. The company said the cases demonstrate MWA as a non-surgical option that can preserve thyroid function and reduce surgical risks.
Baird Medical (NASDAQ: BDMD) highlighted a Johns Hopkins University cost-utility analysis presented at the American Thyroid Association meeting showing that adding transcutaneous thyroid nodule ablation (TNA) to care pathways produced projected cost savings and quality-of-life gains versus surgery or observation.
The health economic model estimated $1,641 per-patient savings for benign nodules and $380 savings for thyroid microcarcinomas over a five-year horizon, while also reporting gains in quality-adjusted life years (QALYs). The study found TNA was the preferred strategy in a substantial majority of modeled scenarios. Baird Medical supported the research and said it will evaluate the findings for potential use in future patient-care developments.
Baird Medical (NASDAQ: BDMD) concluded participation at the ACS Clinical Congress 2025 (October 5–7), showcasing its minimally invasive microwave ablation (MWA) systems to a global surgical audience.
At the exhibit, the company's advanced MWA technology drew significant surgeon interest across specialties, with live demonstrations focused on applications for thyroid nodules, breast disease, and other conditions. The company reported high engagement and renewed discussions with surgical and interventional leaders from leading institutions, and said it will pursue expanded U.S. and international partnerships building on congress momentum.
Baird Medical (NASDAQ: BDMD) is exhibiting at the American College of Surgeons Clinical Congress 2025 in Chicago from October 5–7, 2025. The company is at Booth 1061 presenting live, hands-on demonstrations of its minimally invasive Microwave Ablation (MWA) devices. Demonstrations highlight precision and efficiency for treating thyroid nodules, breast disease, and liver cancer, and aim to engage surgeons and clinical leaders on expanding MWA applications in interventional medicine. Participation underscores Baird Medical's focus on clinical collaboration and advancing patient care through its MWA technology.
Baird Medical (NASDAQ: BDMD) has successfully conducted physician training programs for its Microwave Ablation (MWA) technology at leading U.S. medical centers. The company hosted intensive training sessions at Tulane University and Columbia University to enhance clinical proficiency in thyroid nodule treatment.
At Tulane University, Dr. Emad Kandil led training through five live cases for specialists from multiple institutions. At Columbia University, Dr. Jennifer Kuo conducted specialized courses in May and August, demonstrating successful ablation of large thyroid nodules. The initiative aims to establish MWA as a leading treatment option for thyroid disease.
Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, showcased its innovations at the 2025 American Thyroid Association Annual Meeting. The company's exhibition featured live demonstrations of their MWA systems and attracted physicians from the U.S., Europe, and South America.
A highlight was the Expo Theater session featuring Dr. Emad Kandil from Tulane University, who presented data from over 200 MWA procedures. Notably, the presentation included evidence of MWA's effectiveness in 19 patients where previous Radiofrequency Ablation (RFA) treatments had failed. Dr. Kandil endorsed MWA as a safe and effective treatment for both benign and malignant thyroid nodules across adult and pediatric populations.
Baird Medical (NASDAQ: BDMD) participated in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES) from May 17-19, 2025, in Milwaukee, Wisconsin. The company, specializing in Microwave Ablation (MWA) technology, showcased its innovative MWA system for thyroid nodule treatment at the event.
The presentation highlighted the system's advantages as a minimally invasive alternative to traditional surgery, including reduced procedural risks, preserved thyroid function, and faster recovery times. The company engaged with attending surgeons to gather feedback on practical aspects such as patient selection, ultrasound guidance optimization, and various application scenarios.
Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced training session and academic exchange in New Orleans. The program featured collaboration between Dr. Emad Kandil, Professor at Tulane University School of Medicine, and Dr. Gregory Randolph, Professor at Harvard Medical School and Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology.
During the May 9, 2025 event, the experts engaged in academic discussions on thyroid-focused topics, conducted clinical observations, and performed hands-on procedures. The initiative is part of Baird Medical's strategy to promote excellence in thyroid care through partnerships with medical leaders and support global adoption of minimally invasive therapies.